Abstract
Background Influenza is a major year-round cause of respiratory illness in Kenya, particularly in children under 5. Current influenza vaccines result in short-term, strain-specific immunity and were found in a previous study not to be cost-effective in Kenya. However, next generation vaccines are in development that may have a greater impact and cost-effectiveness profile.
Methods We expanded a model previously used to evaluate cost-effectiveness of seasonal influenza vaccines in Kenya to include next generation vaccines by allowing for enhanced vaccine characteristics and multi-annual immunity. We specifically examined vaccinating children under 5 years of age with improved vaccines, evaluating vaccines with combinations of increased vaccine effectiveness, cross protection between strains (breadth) and duration of immunity. We evaluated cost-effectiveness using incremental cost-effectiveness ratios (ICERs) and incremental net monetary benefits (INMBs) for a range of values for the willingness-to-pay (WTP) per DALY averted. Finally, we estimated threshold per-dose vaccine prices at which vaccination becomes cost-effective.
Results Next generation vaccines can be cost-effective, dependent on the vaccine characteristics and assumed WTP thresholds. Universal vaccines (assumed to provide long-term and broad immunity) are most cost-effective in Kenya across three of four WTP thresholds evaluated, with the lowest median value of ICER per DALY averted ($263, 95% Credible Interval (CrI): $-1698, $1061) and the highest median INMBs. At a WTP of $623, universal vaccines are cost-effective at or below a median price of $5.16 per dose (95% CrI: $0.94, $18.57). We also show that the assumed mechanism underlying infection-derived immunity strongly impacts vaccine outcomes.
Conclusion This evaluation provides evidence for country-level decision makers about future next generation vaccine introduction, as well as global research funders about the potential market for these vaccines. Next generation vaccines may offer a cost-effective intervention to reduce influenza burden in low-income countries with year-round seasonality like Kenya.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by the Wellcome Trust, Centers for Disease Control and Prevention and Taskforce for Global Health via the grant Modeling cost-effectiveness of improved seasonal influenza vaccines in two exemplar countries. JB was funded by PIVI and CDC. EvL and RME were also supported by the National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU) in Modelling and Health Economics, a partnership between UK HSA, Imperial College London, and LSHTM (grant number NIHR200908) and EvL was also supported by the European Union's Horizon 2020 research and innovation programme - project EpiPose (101003688).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study only used publically availble data that were orginially located in the Supplement of Dawa et al. (2020). https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-020-01687-7#Sec18
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used is available in the Supplement of Dawa et al. (2020).
https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-020-01687-7#Sec18
List of Abbreviations
- CrI
- Credible Interval
- DALY
- disability-adjusted life years
- E
- Exposed
- GDP
- gross domestic product
- HA
- haemagglutinin
- I
- infectious
- ICER
- incremental cost-effectiveness ratio
- INMB
- incremental net monetary benefits
- LMIC
- lower middle-income countries
- LRTI
- lower respiratory tract infections
- NH
- Northern Hemisphere
- NIAID
- National Institute of Allergy and Infectious Diseases
- PPC
- Preferred product characteristics
- R
- recovered
- Rv
- Recovered-vaccinated
- S
- Susceptible
- SARI
- severe acute respiratory illness
- SH
- Southern Hemisphere
- Sv
- Susceptible-vaccinated
- URTI
- upper respiratory tract infections
- USD
- US Dollars
- VE
- Vaccine efficacy
- WHO
- World Health Organisation
- WTP
- Willingness-to-pay
